Phylogenetic analysis and phenotypic characterisatics of two Tibet EV-C96 strains.


Journal

Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645

Informations de publication

Date de publication:
29 03 2019
Historique:
received: 05 07 2018
accepted: 22 03 2019
entrez: 30 3 2019
pubmed: 30 3 2019
medline: 22 5 2019
Statut: epublish

Résumé

Enterovirus C96 (EV-C96) is a newly named type of enterovirus belonging to species C, and the prototype strain (BAN00-10488) was firstly isolated in 2000 from a stool specimen of a patient with acute flaccid paralysis in Bangladesh. In this study, we report the genomic and phenotypic characteristics of two EV-C96 strains isolated from individuals from the Tibet Autonomous Region of China. Human rhabdomyosarcoma (RD), human laryngeal epidermoid carcinoma (HEp-2), and human cervical cancer (Hela) cells were infected with the Tibet EV-C96 strains, and enterovirus RNA in the cell culture was detected with a real time RT-PCR-based enterovirus screening method. The temperature sensitivity of Tibet EV-C96 strains were assayed on a monolayer of RD cells in 24-well plates. Full-length genome sequencing was performed by a 'primer-walking' strategy, and the evolutionary history of EV-C96 was studied by maximum likelihood analysis. Strain 2005-T49 grew in all three kinds of cells, and it was not temperature sensitive. In contrast, none of the three cells produced CPE for strain 2012-94H. Phylogenetic analysis of the two Tibetan viruses, other EV-C96 strains, and EV-C prototypes showed that EV-C96 strains were grouped into three clusters (Cluster1-3) based on their VP1 sequences, which may represent three genotypes. Phylogenetic trees based on the P2 and P3 regions highlighted the difference between Chinese EV-C96 strains and the EV-C96 prototype strain BAN-10488. All Chinese strains formed a cluster separate from BAN-10488, which clustered with CV-A1/CV-A22/CV-A19. There is genetic variability between EV-C96 strains which suggest that at least few genetic lineages co-exist and there has been some degree of circulation in different geographical regions for some time. Some recombination events must have occurred during EV-C96 evolution as EV-C96 isolates cluster with different EV-C prototype strains in phylogenetic trees in different genomic regions. However, recombination does not seem to have occurred frequently as EV-C96 isolates from different years and locations appear to cluster together in all genomic regions analysed. These findings expand the understanding of the characterization of EV-C96 and are meaningful for the surveillance of the virus.

Sections du résumé

BACKGROUND
Enterovirus C96 (EV-C96) is a newly named type of enterovirus belonging to species C, and the prototype strain (BAN00-10488) was firstly isolated in 2000 from a stool specimen of a patient with acute flaccid paralysis in Bangladesh. In this study, we report the genomic and phenotypic characteristics of two EV-C96 strains isolated from individuals from the Tibet Autonomous Region of China.
METHODS
Human rhabdomyosarcoma (RD), human laryngeal epidermoid carcinoma (HEp-2), and human cervical cancer (Hela) cells were infected with the Tibet EV-C96 strains, and enterovirus RNA in the cell culture was detected with a real time RT-PCR-based enterovirus screening method. The temperature sensitivity of Tibet EV-C96 strains were assayed on a monolayer of RD cells in 24-well plates. Full-length genome sequencing was performed by a 'primer-walking' strategy, and the evolutionary history of EV-C96 was studied by maximum likelihood analysis.
RESULTS
Strain 2005-T49 grew in all three kinds of cells, and it was not temperature sensitive. In contrast, none of the three cells produced CPE for strain 2012-94H. Phylogenetic analysis of the two Tibetan viruses, other EV-C96 strains, and EV-C prototypes showed that EV-C96 strains were grouped into three clusters (Cluster1-3) based on their VP1 sequences, which may represent three genotypes. Phylogenetic trees based on the P2 and P3 regions highlighted the difference between Chinese EV-C96 strains and the EV-C96 prototype strain BAN-10488. All Chinese strains formed a cluster separate from BAN-10488, which clustered with CV-A1/CV-A22/CV-A19.
CONCLUSIONS
There is genetic variability between EV-C96 strains which suggest that at least few genetic lineages co-exist and there has been some degree of circulation in different geographical regions for some time. Some recombination events must have occurred during EV-C96 evolution as EV-C96 isolates cluster with different EV-C prototype strains in phylogenetic trees in different genomic regions. However, recombination does not seem to have occurred frequently as EV-C96 isolates from different years and locations appear to cluster together in all genomic regions analysed. These findings expand the understanding of the characterization of EV-C96 and are meaningful for the surveillance of the virus.

Identifiants

pubmed: 30922336
doi: 10.1186/s12985-019-1151-7
pii: 10.1186/s12985-019-1151-7
pmc: PMC6439968
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

40

Références

Virus Genes. 2015 Apr;50(2):177-88
pubmed: 25537948
J Gen Virol. 2013 Sep;94(Pt 9):2017-2028
pubmed: 23804569
J Gen Virol. 2002 Jul;83(Pt 7):1721-1728
pubmed: 12075091
J Virol. 2005 Oct;79(20):12650-7
pubmed: 16188967
J Gen Virol. 2012 Nov;93(Pt 11):2357-2362
pubmed: 22894922
J Virol. 1999 Jan;73(1):152-60
pubmed: 9847317
PLoS One. 2013;8(1):e55480
pubmed: 23383202
PLoS One. 2013 Apr 18;8(4):e61451
pubmed: 23637836
Arch Virol. 2014 Feb;159(2):359-64
pubmed: 24013237
J Gen Virol. 2009 Jul;90(Pt 7):1713-1723
pubmed: 19264596
PLoS One. 2014 Jan 30;9(1):e86877
pubmed: 24497989
N Engl J Med. 2013 Nov 21;369(21):1981-90
pubmed: 24256377
RNA. 1995 Dec;1(10):985-1000
pubmed: 8595564
Virus Genes. 2011 Jun;42(3):323-30
pubmed: 21318238
J Virol. 1994 Jul;68(7):4384-91
pubmed: 8207812
PLoS One. 2014 Jan 24;9(1):e86883
pubmed: 24475191
Sci Rep. 2016 Sep 19;6:33595
pubmed: 27642136
J Gen Virol. 2013 Sep;94(Pt 9):1995-2004
pubmed: 23761409
Emerg Microbes Infect. 2016 Sep 21;5(9):e104
pubmed: 27651091
Microbiol Rev. 1996 Sep;60(3):499-511
pubmed: 8840784
J Gen Virol. 2005 May;86(Pt 5):1391-1401
pubmed: 15831951
Sci Rep. 2017 Feb 23;7:43080
pubmed: 28230168
Virus Res. 1992 Aug;24(3):277-96
pubmed: 1329370
Nucleic Acids Res. 1997 Mar 1;25(5):925-32
pubmed: 9023100
Arch Virol. 2009;154(7):1157-61
pubmed: 19526351
J Gen Virol. 2006 Jan;87(Pt 1):119-28
pubmed: 16361424
Sci Rep. 2015 Nov 25;5:17291
pubmed: 26603565
J Gen Virol. 2007 Sep;88(Pt 9):2520-6
pubmed: 17698662
J Virol. 1999 Mar;73(3):1941-8
pubmed: 9971773
J Clin Microbiol. 2000 Mar;38(3):1170-4
pubmed: 10699015
J Med Virol. 2008 Apr;80(4):670-9
pubmed: 18297723
Nat Methods. 2017 Jun;14(6):587-589
pubmed: 28481363
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
J Virol. 1994 Dec;68(12):8089-101
pubmed: 7966599
PLoS One. 2014 Apr 10;9(4):e94579
pubmed: 24722726
PLoS One. 2014 Apr 02;9(4):e93737
pubmed: 24695547
Virol J. 2010 Jun 25;7:138
pubmed: 20579343
Methods Mol Biol. 2016;1387:213-26
pubmed: 26983736
RNA. 1998 May;4(5):520-9
pubmed: 9582094
PLoS Pathog. 2015 Nov 12;11(11):e1005266
pubmed: 26562151
Virus Genes. 2012 Oct;45(2):207-17
pubmed: 22743820
J Clin Microbiol. 1999 May;37(5):1288-93
pubmed: 10203472

Auteurs

Lan Hu (L)

WHO WPRO Regional Polio Reference Laboratory and NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Department of the Laboratory, Guanghua Hospital of Traditional and Western Medicine, Changning District, Shanghai, People's Republic of China.

Yong Zhang (Y)

WHO WPRO Regional Polio Reference Laboratory and NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China. yongzhang75@sina.com.

Mei Hong (M)

Tibet Center for Disease Control and Prevention, Lhasa City, Tibet Autonomous Region, People's Republic of China.

Qin Fan (Q)

WHO WPRO Regional Polio Reference Laboratory and NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Zhejiang Center for Disease Control and Prevention, Hangzhou city, Zhejiang Province, People's Republic of China.

Dongmei Yan (D)

WHO WPRO Regional Polio Reference Laboratory and NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.

Shuangli Zhu (S)

WHO WPRO Regional Polio Reference Laboratory and NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.

Dongyan Wang (D)

WHO WPRO Regional Polio Reference Laboratory and NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.

Wenbo Xu (W)

WHO WPRO Regional Polio Reference Laboratory and NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China. wenbo_xu1@aliyun.com.
Anhui University of Science and Technology, Hefei city, Anhui Province, People's Republic of China. wenbo_xu1@aliyun.com.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH